Literature DB >> 17970830

Spinal cord long-term potentiation is attenuated by the NMDA-2B receptor antagonist Ro 25-6981.

L M Pedersen1, J Gjerstad.   

Abstract

AIM: The NR2B-containing N-methyl-d-aspartate (NMDA) receptors may be involved in a variety of phenomena including synaptic plasticity, memory formation and pain perception. Here we used the NMDA-2B receptor antagonist Ro 25-6981 to investigate the role of the NR2B-containing NMDA receptors in spinal nociception.
METHODS: Extracellular single unit recordings were performed from dorsal horn wide dynamic range (WDR) neurones in intact urethane-anaesthetized Sprague-Dawley rats. The responses of the WDR neurones evoked by C-fibre activation after sciatic nerve stimulation were defined according to latencies. To block the dorsal horn NMDA-2B receptors, the antagonist Ro 25-6981 was applied topically onto the spinal cord. High-frequency stimulation (HFS) of the sciatic nerve was used to induce spinal long-term potentiation (LTP).
RESULTS: Spinal administration of the NMDA-2B receptor antagonist Ro 25-6981 had a clear antinociceptive effect at the spinal level (P < 0.05, C-fibre evoked responses after 4 mm Ro 25-6981 vs. C-fibre evoked responses in baseline). Moreover, spinal administration of this antagonist clearly attenuated the magnitude of spinal cord LTP after HFS conditioning (P < 0.05, C-fibre evoked responses after HFS vs. C-fibre evoked responses after 8 mm Ro 25-6981 + HFS).
CONCLUSION: The present study indicates that expression of full LTP in dorsal horn neurones obtained by HFS conditioning may be dependent on the NMDA receptors containing the NR2B subunit. This suggests that activation of dorsal horn NR2B-containing NMDA receptors may be involved in use-dependent sensitization at the spinal level.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970830     DOI: 10.1111/j.1748-1716.2007.01756.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  19 in total

1.  Estrogen facilitates spinal cord synaptic transmission via membrane-bound estrogen receptors: implications for pain hypersensitivity.

Authors:  Yan Zhang; Xiao Xiao; Xiao-Meng Zhang; Zhi-Qi Zhao; Yu-Qiu Zhang
Journal:  J Biol Chem       Date:  2012-08-06       Impact factor: 5.157

2.  Activation of 5-HT and NR2B contributes to visceral hypersensitivity in irritable bowel syndrome in rats.

Authors:  Ming-Xian Chen; Yu Chen; Rui Fu; Sai-Yue Liu; Qin-Qin Yang; Tang-Biao Shen
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 3.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 4.  Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.

Authors:  Long-Jun Wu; Min Zhuo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 5.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

Review 6.  Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy.

Authors:  Ruth Ruscheweyh; Oliver Wilder-Smith; Ruth Drdla; Xian-Guo Liu; Jürgen Sandkühler
Journal:  Mol Pain       Date:  2011-03-28       Impact factor: 3.395

Review 7.  Neuronal and microglial mechanisms of neuropathic pain.

Authors:  Min Zhuo; Gongxiong Wu; Long-Jun Wu
Journal:  Mol Brain       Date:  2011-07-30       Impact factor: 4.041

8.  Effects of Electroacupuncture on N-Methyl-D-aspartate Receptor-Related Signaling Pathway in the Spinal Cord of Normal Rats.

Authors:  Ha-Neui Kim; Yu-Ri Kim; Ji-Yeon Jang; Hwa-Kyoung Shin; Byung-Tae Choi
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-08       Impact factor: 2.629

9.  Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model.

Authors:  Yu-e Sun; Liangyu Peng; Xiaofeng Sun; Jinhua Bo; Dong Yang; Yaguo Zheng; Chenglong Liu; Beibei Zhu; Zhengliang Ma; Xiaoping Gu
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Agmatine requires GluN2B-containing NMDA receptors to inhibit the development of neuropathic pain.

Authors:  Cristina D Peterson; Kelley F Kitto; Harsha Verma; Kelsey Pflepsen; Eric Delpire; George L Wilcox; Carolyn A Fairbanks
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.